distributor like fare better
healthcar
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
develop highli scalabl pharmaceut
platform address comprehens sourc distribut
need manufactur provid employe
electron inventori platform compani equip ship
million product day world-wide global scale
sheer pharmaceut volum enabl compani
negoti competit price effici provid access
vast portfolio drug core busi roughli
revenu focus pharmaceut distribut
balanc revenu attribut acquir busi
handl roughli third drug sold
unit state creat extens footprint
physician-administ product key anchor custom
within commun compani oper effici
highli regul environ provid insul
core busi distribut servic larg driven drug
price drug mix gener versu brand drug overal
volum deceler pharmaceut drug growth due
slower brand drug inflat shift mix favor gener
drug lower price slower introduct blockbust drug
increas provid negoti leverag oper margin
pressur high cost specialti
pharmaceut drug off-set declin stem
introduct fewer brand drug overal oper
margin rel displac brand drug like lower
tout highest concentr among
competitor specialti drug repres roughli overal
revenu like help compani grow slightli faster
competitor recent similar two largest
distributor compani grown signific size
regular acquisit like necessari supplement growth
off-set overal market deceler slower growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
lead global third-parti logist provid
engag wholesal pharmaceut sourc distribut specialti
brand-nam gener pharmaceut relat servic
acute-car hospit health system independ chain retail
pharmaci mail order pharmaci medic clinic long-term care
altern site pharmaci physician practic dialysi clinic
healthcar custom acquir smaller compani manag
attain abil compound steril prepar distribut veterinari
pharmaceut vaccin transport biopharmaceut provid
inventori reimburs consult servic provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
maintain per share fair valu estim
impli fiscal
ev/adjust ebitda time free cash flow yield
price-to-earnings multipl short term
believ healthcar distributor benefit
unpreced volum relat
bolster profit scale oper expens
revenu driver price volum mix
disclos made sever assumpt project
industri growth except potenti extern
market shock anticip market share shift
dramat near term result anticip
overal annual top-lin growth roughli larg
benefit growth specialti pipelin
increas number therapi age popul
brand drug
compon growth varieti factor includ
neg slower growth introduct
new drug lesser extent gener
deflat
lower spend hepat
prescript opioid factor net anticip
industri revenu growth roughli
similar industri rang accord iqvia
expect revenu growth continu slow
declin histor compani growth high
singl digit histor revenu growth continu
lumpi due mix drug introduct inflat
gener albeit less industri roughli
howev lower gener price point would translat
roughli half overal pharmaceut distribut revenu
declin
fiscal model oper
margin declin fiscal
next five year
part valuat framework addit
base-cas dcf also model bull bear case
valuat scenario critic debat
surround compani abil entrench exist
partnership manufactur
negoti provid
financ
inventori manag servic
provid negoti provid specialti drug distribut
base current high level custom concentr
increas competit environ potenti
regulatori chang believ limit upsid
base scenario per share
bull-cas fair valu estim per share
growth overal revenu project
grow basi point higher base scenario
drive net growth slightli anticip industri
project scenario oper margin
anticip improv basi point due increas
revenu higher averag profit
bear-cas fair estim per share scenario
inflat increas volum slightli offset
price deflat lower growth anticip decreas
oper margin basi point signific
legisl regulatori chang extern shock
increas uncertainti downsid
last three four year oper margin
industri declin oper margin
uncertainti rate pharmaceut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
provid retail pharmaci requir infrastructur
regulatori hurdl requir logist manag
insul new entrant
cardin health
repres market role pharmaceut
distributor evolv increas number new
therapi format govern regulatori organ
regulatori requir licensur manufactur
retail pharmaci pharmaceut distributor
evolut compani continu invest
physic infrastructur provid logist
support effici compani scale also provid
abil negoti lower price drug manufactur
across comprehens portfolio gener brand
specialti drug behalf provid acut hospit
clinic mail pharmaci retail pharmaci
financ function provid manufactur
support commerci manufactur invest
autom infrastructur escal past
decad invest nearli
billion capit expenditur billion
acquisit billion strengthen foothold
merger amerisourc health bergen brunswig
slightli differ geographi creat larger entiti
stronger nation presenc sinc initi merger
compani made dozen acquisit rang
contract packag courier servic temperature-control
item world courier group home infus igg america
lead anim pharmaceut vaccin distributor
mwi veterinari suppli addit sever smaller
focus pharmaceut
distribut acquisit provid increment
distributor stand medium due competit
environ potenti extern shock includ
legisl chang increas price transpar
potenti entranc new competitor
attribut cost advantag
effect oper oligopoli
entrench within custom base
largest pharmaceut distributor global contract
manufactur capabl vertic integr
provid retail pharmaci chain canada
europ closest pure-play
pharmaceut distributor platform base insid
close provid retail pharmaci cardin
smallest three private-label
commod manufactur capabl medic devic
compani invest infrastructur provid
abil navig highli regul drug market scale
also enabl compani negoti behalf
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
revenu channel limit growth potenti
special natur success
acquisit around specialti account
increas percentag overal volum due rapid
acceler new specialti drug
manufactur product
commod natur servic reflect low
oper margin despit low margin compani
enjoy return invest capit larg
due scale growth driven strong drug inflat
pharmaceut revenu declin slower
inflat shift revenu mix margin like
declin increas negoti leverag
custom rise healthcar consolid
amerisourc top custom repres
revenu oper margin declin exacerb
rise govern scrutini acquir busi
drug compound factor weigh roic
despit near-term improv trend like
persist
current lack price transpar signific
variat list invoic price day-to-day
price volatil regulatori complianc recal
provid retail pharmaci
infrastructur quickli manag avail inform
negoti competit price manufactur
amerisourc volum also provid abil negoti
lower price drug manufactur increment scale
abil provid assist
inventori manag complianc financ
convers compani also support commerci
new drug deliveri product manufactur
custom leverag limit narrow recent
howev pharmaceut revenu declin
slower inflat shift revenu mix increas
gener versu brand drug meanwhil margin
declin like due part increas negoti
leverag custom driven healthcar provid
consolid expect oper margin pressur
trend rate despit short-term benefit
unpreced demand surg due coronaviru
insul provid compani amass
physic infrastructur complex regulatori environ
overal market pressur like resum due
declin reimburs healthcar consolid
declin overal pharmaceut growth build
reimburs pressur manufactur provid
press focu contain cost result
pharmaceut distribut client activ solicit
bid negoti better price commod servic
distributor also includ client gener sourc
joint ventur red oak sourc cardin
walgreen
claruson healthcar consolid
also increas concentr pharmaceut
distribut custom top amerisourcebergen
custom repres revenu market
pressur increas leverag pharmaceut
distributor custom like largest contributor
deterior overal industri margin
declin consecut last three four year even
manufactur appear test altern
direct shipment matur drug may limit
could also neg factor
secur moat due scale
uncertain drug price environ grow
signific declin pharmaceut market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
growth caus distributor seek altern
channel acquisit entri new
area outsid core compet prove costli
compound busi acquir pharmedium sinc
regulatori scrutini compound increas
compani close largest site earli
continu expand new area
remain relev off-set declin core busi
execut regulatori risk increas concern
addit extern shock highli contest
reduct rebat increas price transpar
would diminish pharmaceut distributor
valu negoti transpar price
provid manufactur would less like need middl
man negoti rate would give custom
leverag renegoti distribut contract
amazon may immedi threat next sever
year discount altogeth
signific resourc appear method
gather expertis compet healthcar distribut
amazon signific inventori manag expertis
quietli accumul core piec need
compet pharmaceut distributor includ
pillpack state distributor licens joint
ventur jpmorgan berkshir hathaway
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
key drug distributor handl
third pharmaceut distribut market
compani infrastructur provid scale abil
effect negoti price provid
inventori
oth compani servic enabl provid
manufactur focu core busi
outsourc logist drug highli
requir high sunk cost low oper margin
provid barrier entri highli matur
rivalri
declin reimburs matur market could
limit growth pressur profit
compani continu make acquisit
outsid core compet seek altern
channel growth execut regulatori risk
oextern shock legisl action increas
drug price transpar entranc
competitor could disrupt current oligopoli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ enjoy posit solid
financi strength aris strong balanc sheet
posit matur market fiscal
billion cash
equival off-set billion debt result net debt
billion debt/capit ratio less fiscal
gross leverag time adjust ebitda free
cash flow gener billion fiscal
compani regularli complet acquisit increas
cross-sel opportun exist custom fuel
growth manag spent roughli billion
averag acquisit last four fiscal year
acceler histor trend annual common
stock dividend averag million last
year yield two peer
repurchas nearli billion
worth stock fiscal fiscal
million buyback fiscal manag roughli
author believ compani continu
repurchas share exist author
remain
share
oper matur oligopoli
loss larg custom high custom concentr
regulatori chang signific litig opioid entri
new competitor signific resourc overal market
dynam could reduc abil negoti drug
manufactur custom continu pressur
drug price pose risk compani includ
deflat gener drug price increas gener mix
slower growth pharmaceut pipelin lower
spend hepat opioid risk could eman
propos govern rule seek increas
transpar drug price elimin rebat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
cost drug current pass-through
revenu basi pharmaci wholesal
compens although pharmaci distributor would
opportun negoti drugmak provid
uncertainti abil negoti
industri rate paid current
transpar continu consolid
pharmaci could affect compani abil negoti
lower price cornerston servic
although threat new competitor immin
amazon compani signific inventori manag
expertis quietli accumul core piec
need compet pharmaceut distributor unlik
distributor
investor walgreen equiti stake also
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
share
fund
share
fund
stewardship rate overal season leader
divers background pharmaceut distribut
see govern issu
steven colli chairman presid chief execut
offic join compani specialti
pharmaci distribut segment signific
contributor key area growth compani
colli accumul year
experi pharmaci distribut
jame cleari jr execut vice presid chief
financi offic core member mwi veterinari
suppli compani acquir
sinc acquisit increas
respons execut vice presid group
presid global commerci servic
anim health segment current role cfo
robert mauch execut vice presid group presid
pharmaceut distribut strateg global sourc
join compani acquisit xcenda
founder year healthcar
experi sinc acquisit assist improv
custom experi compani oper chief
oper offic execut vice presid
presid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
term suppli chain pull take
base account healthcar provid remain
stretch address unpreced
volum gross charg hospit set could
high billion associ pandem
influenza cost accord fair health although
region doubl count may inflat estim
agre direct surg expect unusu
high volum translat short-term gain
distributor anticip advers mix shift toward
commod item hoard suppli increas
charges/fe associ special handl
highli demand product net neutral revenu
perform penalti like waiv expect
volum fall bottom line distributor
model scale longer term anticip mix volum
return histor norm provid focu
anticip cardin health
realiz increas profit near
term maintain long-term outlook fair valu
estim cardin health rais
rais normal
ep rais
normal ep
convers believ walgreen abl
scale effici roll strateg
partnership like slower expect
consum brick mortar compani like incur
higher staf shrinkag overhead store theft
offset higher gross margin flux
profit front end hoard item work
system foot traffic like strain
increas consum confid on-line option
result trim fiscal estim fair valu
estim compani maintain attract
dividend yield
report messi quarter plan
shutter compound maintain fve
quarterli earn ahead estim
capitalq consensu larg benefit
expect tax rate increas share repurchas partial
off-set lower-than-expect oper margin revenu
predominantli driven specialti drug revenu growth
higher express script volum attribut
integr acquisit lesser extent
double-digit growth significantli smaller
segment anim health consult manag also
announc shut compound segment
sever year fail remedi overcom
share intra-day trade roughli
high expect share remain highli
volatil mount pressur specialti drug mix
shift yield significantli lower margin along
extern shock factor includ potenti risk
liquid largest sharehold walgreen around
continu seek go privat much
lesser extent opioid litig seem
final leg negoti base better-than-expect
share repurchas reduct pharmedium remedi
effort slightli better-than-expect tax benefit
quarter rais normal ep estim
despit notabl increas fiscal
ep estim roughli half benefit
attribut better-than-expect share repurchas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
level despit oper margin benefit associ
wind compound unit lower
project gross margin fiscal year outer year
reflect continu pressur revenu mix shift
maintain fair valu estim
surpris manag plan shutter
pharmedium sub-seg busi acquir
year ago billion sinc initi merger
form compani made dozen
acquisit rang contract packag courier
servic temperature-control item world courier
group home infus igg america oncolog support
pharmaceut vaccin distributor mwi veterinari
suppli addit sever smaller acquisit similar
peer struggl provid value-ad
servic custom made rash
acquisit tune billion exclud oper
invest associ integr past five
acquisit supplement core
distribut oper continu neg
pressur gross margin although three distributor
oper oligopoli highli regul environ
anticip signific declin market share
full-year rais provid boost industri
share maintain fair valu estim jan
previou guidanc midpoint boost share price
three distributor -- cardin
-- toward high driver
guidanc rais reson market growth trend
comment healthcar peer suggest stabil
gener price mid-single-digit brand
continu strength specialti expand role
pharmaceut distributor stronger-than-
expect posit market reaction departur
overal investor pessim segment
fuel continu opioid litig drug polici
reflect
strength core pharmaceut market includ
continu double-digit growth specialti subseg
increas fiscal normal ep estim
reflect stronger initi
expect top-lin growth back half fiscal year
gener aid better-than-expect cost save
benefit maintain long-term growth rate
slim profit group fair valu
estim share although
best posit distributor provid initi step
improv coordin care evolut value-
base reimburs remain cautiou distributor
group whole
report solid fourth-quart result specialti
scale remain distribut
result larg line estim
capitalq consensu benefit better revenu
growth lower expect tax rate continu share
repurchas partial off-set
oper margin revenu growth driven specialti
lesser extent double-digit growth
significantli smaller segment unlik mckesson
recent quarterli perform advers impact
mix shift toward
amerisourc appear better manag revenu
mix shift quarter offset wrap-around servic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
result flat adjust oper profit year year
fiscal revenu anticip grow mid- high-
single-digit anim servic consult
peg higher roughli one quarter volum increas
core distribut segment express script
integr like pressur margin
specialti mail tend gener lower margin
expect share remain volatil build pressur
increas specialti mix yield lower margin
along extern shock factor includ potenti
liquid risk largest sharehold walgreen
seek altern lesser extent opioid
litig base fiscal adjust dilut ep
guidanc lower estim
reflect increas revenu mix shift
also tweak outer year estim increment
upward reflect stabil brand gener
price increas specialti volum lack
pharmaceut drug transpar continu bolster
growth key distributor reinforc
belief scale matter drug distribut maintain
fair valu estim
like leader specialti drug
sale may slightli larger market share
largest pharmaceut drug distributor
broken believ specialti drug revenu
like exceed total revenu like grow
materi onboard increment express
script volum come quarter quarter
amerisourc effect manag wrap around servic
off-set advers impact addit specialti
drug lower oper margin increment
mail volum near term also need activ
settlement bellweth feder trial
provid much-need relief teva oct
instead kick much-await feder opioid trial
oct would influenc outcom
case million settlement four
five defend three distributor teva
two ohio counti affect opioid epidem
cuyahoga summit announc court
initi teva term disclos includ
cash payment million donat
million opioid treatment medic three-year
period understand teva also settl principl
north carolina pennsylvania tennesse texa
increment inform forthcom although
guidanc provid extrapol
announc payment tent settlement provid
investor relief sinc market price
financ crunch settlement meaning step
toward global settlement remov teva
defend track litig schedul proceed
earli share close nearli news
landmark settlement ahead feder court kickoff
surpris public pharmaceut compani take
step distanc highli charg
polit matter remov largest overhang
share due time constraint move piec
initi settlement probabl came premium
continu believ increment settlement
requir up-front payment rather spread
multipl year manag compani
cover revisit sensit fair valu estim
figur releas maintain no-moat
high uncertainti rate fair valu estim teva
pleas see aug oct note background
decade-old opioid content pharmaceut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
